Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2007-10-09
2007-10-09
Meller, Michael (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
11452095
ABSTRACT:
Disclosed are novel anti-inflammatory pharmaceutical compositions and related methods that exhibit potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation can comprise a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and can fall within the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.
REFERENCES:
patent: 4640841 (1987-02-01), Forster et al.
patent: 5955086 (1999-09-01), DeLuca et al.
patent: 8286745 (1983-02-01), None
patent: 1294183 (2001-05-01), None
Patrignani, Paola, “Biochemical and Pharmacological Characterization of the Cyclooxygenase Activity of Human Blood Prostaglandin Endoperoxide Synthases,” Journal of Pharmacology and Experimental Therapeutics, 1994, pp. 1705-1711, vol. 271, No. 3.
Wolfe, M. Michael, M.D. et al, “Gastrointestinal Toxicity of Nonsteroidal Antinflammatory Drugs”, New England Journal of Medicine, vol. 340, No. 24, pp. 1888-1899, Jun. 17, 1999.
Brooks, P. et al. “Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2”, British Society for Rheumatology, vol. 38, pp. 779-788, 1999.
Warner, Timothy D. et al. “Nonsteroid drug selectivities for cylco-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis”, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 7563-7568, Jun. 1999.
Yasukawa, Ken et al. “Humulon, a Bitter in the Hop, Inhibits Tumor Promotion by 12-0-Tetradecanoylphorbol-13-Acetate in Two-Stage Carcinogenesis in Mouse Skin”, Oncology, vol. 52, pp. 156-158, 1995.
Yamamoto, Kei et al. “Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid”, Federation of European Biochemical Societies, vol. 465, pp. 103-106, 2000.
Wallace, J.L. et al., “NSAID-Induced Gastric Damage in the rat: Requirement for Inhibition of Both Cyclooxygenase-1 and Cyclooxygenase-2”, Gastroenterology, vol. 119, pp. 706-714, 2000.
Lipoprotein Technologies, Inc.
Meller Michael
Thorpe North & Western LLP
LandOfFree
Methods of administering anti-inflammatory cyclooxygenase-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of administering anti-inflammatory cyclooxygenase-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering anti-inflammatory cyclooxygenase-2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891537